

*Development Status:* The technology is currently in the pre-clinical stage of development.

*Inventors:* Robert C. Moschel (NCI) *et al.*

*Relevant Publication:* A manuscript directly related to the above technology will be available as soon as it is accepted for publication.

*Patent Status:* U.S. Patent Application No. 11/683,310 filed 07 Mar 2007 (HHS Reference No. E-307-2004/1-US-01).

*Licensing Status:* Available for exclusive and non-exclusive licensing.

*Licensing Contact:* Adaku Nwachukwu, J.D.; 301/435-5560; *madua@mail.nih.gov*.

### **Inhibition of ABC Transporters by Transmembrane Domain Analogs**

*Description of Technology:* ABC transporters contain multiple transmembrane domains and are involved in the translocation of a variety of substrates across cell membranes. Upregulation of these transporters contributes to multiple drug resistance in cancer chemotherapy wherein these transporters export chemotherapeutic agents out of cancer cells. The inventors have found that P-glycoprotein and ABCG2 transporter can be effectively inhibited by properly modified peptides corresponding to certain transmembrane domains. This inhibition can be used to overcome drug resistance in resistant tumors.

*Applications:* Therapeutics that enhance cancer treatments.

*Market:* Cancer is the second leading cause of death in the United States; 600,000 deaths caused by cancer in 2006; Worldwide incidence of new cancer patients is forecast to increase from 4.2 million cases in the major cancer markets in 2005 to 4.6 million in 2010; Global anticancer market was worth over \$42 billion in 2005 and by 2010, the global cancer market is expected to generate sales in excess of \$60 billion.

*Development Status:* The technology is currently in the pre-clinical stage of development.

*Inventors:* Nadya I. Tarasova *et al.* (NCI)

#### *Publications:*

1. NI Tarasova *et al.* Transmembrane inhibitors of P-glycoprotein, an ABC transporter. *J Med Chem.* 2005 Jun 2;48(11):3768-3775.

2. NI Tarasova *et al.* Inhibition of G-protein-coupled receptor function by disruption of transmembrane domain interactions. *J Biol Chem.* 1999 Dec 3;274(49):34911-34915.

*Patent Status:* U.S. Patent Application No. 10/130,192 filed 13 May 2002 (HHS Reference No. E-019-2000/2-US-02);

PCT Patent Application No. PCT/US2000/31817 filed 17 Nov 2000 (HHS Reference No. E-019-2000/2-PCT-01); U.S. Provisional Patent Application No. 60/166,767 filed 22 Nov 1999 (HHS Reference No. E-019-2000/1-US-01); U.S. Provisional Patent Application No. 60/166,382 filed 18 Nov 1999 (HHS Reference No. E-019-2000/0-US-01).

*Licensing Status:* Available for exclusive or non-exclusive licensing.

*Licensing Contact:* Jennifer Wong; 301/435-4633; *wongje@mail.nih.gov*.

*Collaborative Research Opportunity:* The National Cancer Institute's Structural Biophysics Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize inhibitors of multiple drug resistance proteins. Please contact John D. Hewes, Ph.D. at 301-435-3121 or *hewesj@mail.nih.gov* for more information.

Dated: May 21, 2007.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. E7-10332 Filed 5-29-07; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Initial Review Group; Subcommittee F—Manpower & Training; NCI-F.

*Date:* June 13-14, 2007.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007.

*Contact Person:* Lynn M. Amende, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8105, Bethesda, MD 20892, 301-451-4759, *amendel@mail.nih.gov*.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; CA 07-505, "The American College of Radiology Imaging Network (ACRIN) (Limited Competition U01)."

*Date:* June 20-21, 2007.

*Time:* 5 p.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Park Hyatt Philadelphia, Broad and Walnut Streets, Philadelphia, PA 19102.

*Contact Person:* Kenneth L. Bielak, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 7147, Bethesda, MD 20852, 301-496-7576, *bielatk@mail.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 22, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-2664 Filed 5-29-07; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Center on Minority Health and Health Disparities; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Minority Health and Health Disparities.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose